Include All CSL Sites

CSL completes Novartis influenza vaccine acquisition in Germany

Hattersheim, Germany — 02/01/2016

CSL Limited (ASX:CSL; USOTC: CSLLY) today announced the legal close of the acquisition of the Novartis influenza vaccine business in Germany. This transaction follows CSL’s staged acquisition of Novartis’ global influenza vaccine business on 31 July 2015. In Germany, the transaction has been cleared by regulators and local employment councils.

The German business will be combined with CSL’s existing vaccines business, bioCSL, and operate under the brand Seqirus GmbH, effective today.

Seqirus [Sek-eer-us] is the world’s no. 2 influenza vaccine provider in sales with operations in more than 20 countries in the US$4 billion global industry. Seqirus provides a differentiated product portfolio, possesses strong pandemic and prepandemic franchises and manages one of the world’s largest influenza vaccine manufacturing networks with operations on three continents: North America, Europe, and Australia. CSL’s experience with influenza dates back nearly 100 years when it produced vaccine during the Spanish Flu pandemic in 1919.

“We are very pleased that the influenza vaccine business of Novartis in Germany has now joined Seqirus,” said Brent MacGregor, Seqirus Senior Vice President, Commercial Operations. “We are committed to continuing to serve the influenza vaccines market in Germany and are well placed to meet the needs of our customers for future influenza seasons.”

“Importantly, our local management team is committed to ensuring a seamless transition to our new operating structure. We remain focused on maintaining high standards for our customers and patients and supply important products to help protect communities around the world from pandemic threats and seasonal influenza,” MacGregor said.

About Seqirus Seqirus is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, bioCSL and the influenza vaccines of Novartis joined forces to create Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 2,000 employees, significant manufacturing capacity, a commercial presence in 20 countries. 

Media Contacts:

MCG Medical Consulting Group 
Gesellschaft für Medizinberatung mbH & Co. KG
Wiebke Sowen 
Phone: +49 2 11 51 60 45-178 
Cell. +49 1 62 107 35 10
CSL Behring on behalf of Seqirus GmbH 
Hans Herberg 
Senior Manager Communications 
Phone: +49 6421 39 4022